We are a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. These disorders often occur when neurons are overly excited or inhibited, leading to an imbalance, and our focus is on restoring homeostasis. We are developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with broad therapeutic potential to deliver improved therapeutics for patients with these disorders.

Our two lead clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a novel palmitoylethanolamide (PEA) prodrug initially being developed for the treatment of diabetic peripheral neuropathic pain (DPNP) and pain associated with lumbosacral radiculopathy (LSRP, commonly referred to as sciatica). ETX-810 is being evaluated in two Phase 2a clinical trials that are expected to report topline data in the first half of 2022.

(Note: Eliem Therapeutics upsized its IPO at pricing on Aug. 9, 2021, to 6.4 million shares, up from 6 million shares in its amended filing, and priced the stock at $12.50, as planned, to raise $80 million. Earlier in an S-1/A filing dated Aug. 9, Eliem Therapeutics had trimmed its IPO to 6 million shares at $12.50 to raise $75 million – compared with its initial terms of 4.5 million shares at $17 to $19 to raise $81 million. Eliem’s IPO had been originally scheduled for pricing on Thursday, Aug. 5, 2021.)